| Literature DB >> 30979026 |
Frank Doyle1, Karen Morgan2, Mary Mathew3, Princy Palatty4, Prashanti Kamat5, Sally Doherty6, Jody Quigley7, Josh Henderson8, Ronan O'Carroll9.
Abstract
Eliciting different attitudes with survey questionnaires may impact on intention to donate organs. Previous research used varying numbers of questionnaire items, or different modes of intervention delivery, when comparing groups. We aimed to determine whether intention to donate organs differed among groups exposed to different theoretical content, but similar questionnaire length, in different countries. We tested the effect of excluding affective attitudinal items on intention to donate, using constant item numbers in two modes of intervention delivery. Study 1: A multi-country, interviewer-led, cross-sectional randomized trial recruited 1007 participants, who completed questionnaires as per group assignment: including all affective attitude items, affective attitude items replaced, negatively-worded affective attitude items replaced. Study 2 recruited a UK-representative, cross-sectional sample of 616 participants using an online methodology, randomly assigned to the same conditions. Multilevel models assessed effects of group membership on outcomes: intention to donate (primary), taking a donor card, following a web-link (secondary). In study 1, intention to donate did not differ among groups. Study 2 found a small, significantly higher intention to donate in the negatively-worded affective attitudes replaced group. Combining data yielded no group differences. No differences were seen for secondary outcomes. Ancillary analyses suggest significant interviewer effects. Contrary to previous research, theoretical content may be less relevant than number or valence of questionnaire items, or form of intervention delivery, for increasing intention to donate organs.Entities:
Keywords: affective attitudes; organ donation; psychological theory; public health; question-behavior effect; randomized trial
Mesh:
Year: 2019 PMID: 30979026 PMCID: PMC6479820 DOI: 10.3390/ijerph16071304
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Participant flowchart and outcome ascertainment.
Sample description.
| Study 1 | Study 2 | Combined Data | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study 1, N | Study 1, All Groups | Group 1 | Group 2 | Group 3 | Study 2 Overall (N = 612 for All) | Group 1 | Group 2 | Group 3 | Combined Samples | Group 1 | Group 2 | Group 3 | |
| Age (mean, SD) | 1005 | 34.4 (18.1) | 34.6 (17.9) | 34.8 (18.1) | 33.7 (18.2) | 50.4 (15.6) | 50.8 (15.3) | 49.5 (16.1) | 51.0 (15.4) | 40.4 (18.9) | 40.7 (18.7) | 40.6 (18.8) | 40.0 (19.1) |
| Women | 1004 | 54.0% | 50.7% | 56.1% | 55.3% | 50.3% | 51.2% | 52.4% | 47.2% | 52.6% | 50.9% | 54.6% | 52.3% |
| Private health insurance † | 691 | 50.7% | 51.2% | 47.2% | 53.7% | † | † | † | † | - | - | - | - |
| Interview location (anonymized, Ireland only) | 433 | n/a | n/a | n/a | n/a | - | - | - | - | ||||
| 1 | 26.3% | 30.5% | 22.3% | 26.1% | |||||||||
| 2 | 34.2% | 33.8% | 35.2% | 33.6% | |||||||||
| 3 | 27.5% | 23.2% | 32.4% | 26.9% | |||||||||
| 4 | 8.08% | 7.95% | 6.76% | 9.70% | |||||||||
| 5 | 3.93% | 4.64% | 3.38% | 3.73% | |||||||||
| Do you know someone who (% yes) | |||||||||||||
| has received an organ | 992 | 18.2% | 17.0% | 19.0% | 18.5% | 11.1% | 12.0% | 10.6% | 10.8% | 15.5% | 15.1% | 15.7% | 15.7% |
| needs an organ | 997 | 11.9% | 10.0% | 13.6% | 12.3% | 3.59% | 4.78% | 4.33% | 1.54% | 8.76% | 8.01% | 9.92% | 8.40% |
| has donated an organ | 994 | 13.1% | 11.9% | 15.1% | 12.3% | 6.86% | 8.61% | 5.29% | 6.67% | 10.7% | 10.6% | 11.2% | 10.3% |
| Ever donated blood | 998 | 34.6% | 33.1% | 37.3% | 33.4% | 31.2% | 37.3% | 28.9% | 27.2% | 33.3% | 34.7% | 34.0% | 31.2% |
† National health insurance for all citizens in UK; n/a—not applicable.
Summary of outcomes (intention and taking card/website transfer).
| Study 1 | Study 2 | Combined Data | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study 1, N | Study 1, All Groups | Group 1 | Group 2 | Group 3 | Study 2 Overall (N = 612 for All) | Group 1 | Group 2 | Group 3 | Combined Samples | Group 1 | Group 2 | Group 3 | |
| Intention (mean, SD) | 902 | 4.41 (1.60) | 4.44 (1.66) | 4.30 (1.57) | 4.47 (1.56) | 3.25 (1.54) | 3.13 (1.49) | 3.19 (1.56) | 3.44 (1.56) | 3.94 (1.68) | 3.91 (1.72) | 3.83 (1.66) | 4.07 (1.64) |
| Taking donor card (yes, %) | 895 | 48.7% | 46.3% | 51.6% | 48.4% | - | - | - | - | - | - | - | - |
| Transferred to organ donor website | - | - | - | - | - | 7.03% | 6.22% | 6.25% | 8.72% | - | - | - | - |
| Combined behavioral outcome (Taking card or website transfer) | - | - | - | - | - | - | - | - | - | 31.8% | 29.9% | 32.6% | 32.9% |
Results of regression models predicting outcomes.
| Primary Outcome (Intention) | Secondary Outcomes (Card/Website) | |||||||
|---|---|---|---|---|---|---|---|---|
| Intention | β | Std. Err. | 95% CI |
| OR | 95% CI |
| |
| Study 1 | Group 1 | Ref. | - | - | - | Ref. | - | - |
| Group 2 | −0.120 | 0.130 | −0.375 to 0.134 | 0.354 | 1.28 | 0.890 to 1.84 | 0.183 | |
| Group 3 | 0.025 | 0.127 | −0.224 to 0.274 | 0.850 | 1.34 | 0.932 to 1.93 | 0.113 | |
| Study 2 | Group 1 | Ref. | - | - | - | Ref. | - | - |
| Group 2 | 0.061 | 0.150 | −0.234 to 0.355 | 0.686 | 1.00 | 0.426 to 2.03 | 0.990 | |
| Group 3 | 0.307 | 0.153 | 0.007 to 0.606 | 0.044* | 1.44 | 0.680 to 3.05 | 0.341 | |
| Combined data | Group 1 | Ref. | - | - | - | - | - | |
| Group 2 | −0.047 | 0.098 | −0.239 to 0.146 | 0.637 | 1.22 | 0.882 to 1.70 | 0.227 | |
| Group 3 | 0.136 | 0.098 | −0.055 to 0.328 | 0.163 | 1.37 | 0.982 to 1.90 | 0.063 | |
| Exploratory analyses—Irish data only | Group 1 | Ref. | - | - | - | Ref. | - | - |
| Group 2 | −0.124 | 0.199 | −0.514 to 0.266 | 0.533 | 1.55 | 0.916 to 2.63 | 0.102 | |
| Group 3 | −0.184 | 0.207 | −0.590 to 0.221 | 0.373 | 1.52 | 0.877 to 2.63 | 0.136 | |
| Researcher 1 | Ref. | - | - | - | Ref. | - | - | |
| Researcher 2 | −0.809 | 0.250 | −1.30 to −0.319 | 0.001 ** | 0.42 | 0.210 to 0.851 | 0.016 * | |
| Researcher 3 | −0.395 | 0.227 | −0.840 to 0.049 | 0.081 | 0.34 | 0.184 to 0.647 | 0.001 ** | |
| Researcher 4 | 0.283 | 0.235 | −0.177 to 0.745 | 0.227 | 0.63 | 0.326 to 1.22 | 0.174 | |
* p < 0.05, ** p < 0.01; Group 1—replicating INORDAR; Group 2—omitting all affective attitudinal items; Group 3—omitting negatively-worded affective attitudinal items.
| Section/Topic | Item No | Checklist Item | Reported on Page No |
|---|---|---|---|
|
| |||
| 1a | Identification as a randomised trial in the title | 1 | |
| 1b | Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) | 1 (non-structured as per journal requirements) | |
|
| |||
| Background and objectives | 2a | Scientific background and explanation of rationale | 1–3 |
| 2b | Specific objectives or hypotheses | 3 | |
|
| |||
| Trial design | 3a | Description of trial design (such as parallel, factorial) including allocation ratio | 3 |
| 3b | Important changes to methods after trial commencement (such as eligibility criteria), with reasons | 3 | |
| Participants | 4a | Eligibility criteria for participants | 3–4 |
| 4b | Settings and locations where the data were collected | 3,5 | |
| Interventions | 5 | The interventions for each group with sufficient details to allow replication, including how and when they were actually administered | 4–5, TIDIeR checklist |
| Outcomes | 6a | Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed | 5 |
| 6b | Any changes to trial outcomes after the trial commenced, with reasons | No changes | |
| Sample size | 7a | How sample size was determined | 5 |
| 7b | When applicable, explanation of any interim analyses and stopping guidelines | Not applicable | |
| Randomisation: | |||
| Sequence generation | 8a | Method used to generate the random allocation sequence | 5–6 |
| 8b | Type of randomisation; details of any restriction (such as blocking and block size) | 5–6 | |
| Allocation concealment mechanism | 9 | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | 5–6 |
| Implementation | 10 | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | 5–6 |
| Blinding | 11a | If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how | 5–6 |
| 11b | If relevant, description of the similarity of interventions | 4 | |
| Statistical methods | 12a | Statistical methods used to compare groups for primary and secondary outcomes | 6 |
| 12b | Methods for additional analyses, such as subgroup analyses and adjusted analyses | 6 | |
|
| |||
| Participant flow (a diagram is strongly recommended) | 13a | For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome | 7— |
| 13b | For each group, losses and exclusions after randomisation, together with reasons | 7— | |
| Recruitment | 14a | Dates defining the periods of recruitment and follow-up | 5 |
| 14b | Why the trial ended or was stopped | Not applicable | |
| Baseline data | 15 | A table showing baseline demographic and clinical characteristics for each group | 8— |
| Numbers analysed | 16 | For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups | 6,7— |
| Outcomes and estimation | 17a | For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) | 11 |
| 17b | For binary outcomes, presentation of both absolute and relative effect sizes is recommended | 10 | |
| Ancillary analyses | 18 | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory | 11 |
| Harms | 19 | All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) | Not applicable |
|
| |||
| Limitations | 20 | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses | 14 |
| Generalisability | 21 | Generalisability (external validity, applicability) of the trial findings | 13 |
| Interpretation | 22 | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence | 13–14 |
|
| |||
| Registration | 23 | Registration number and name of trial registry | 3 |
| Protocol | 24 | Where the full trial protocol can be accessed, if available | Not applicable |
| Funding | 25 | Sources of funding and other support (such as supply of drugs), role of funders | 14 |
* We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.
| Item Number | Item | Where Located ** | |
|---|---|---|---|
| Primary Paper (Page or Appendix Number) | Other † (Details) | ||
| BRIEF NAME | |||
| 1. | Provide the name or a phrase that describes the intervention. | n/a | _____________ |
| WHY | |||
| 2. | Describe any rationale, theory, or goal of the elements essential to the intervention. | 2–5 | _____________ |
| WHAT | |||
| 3. | Materials: Describe any physical or informational materials used in the intervention, including those provided to participants or used in intervention delivery or in training of intervention providers. Provide information on where the materials can be accessed (e.g., online appendix, URL). | 4–5 | _____________ |
| 4. | Procedures: Describe each of the procedures, activities, and/or processes used in the intervention, including any enabling or support activities. | 5 | _____________ |
| WHO PROVIDED | |||
| 5. | For each category of intervention provider (e.g., psychologist, nursing assistant), describe their expertise, background and any specific training given. | 5–6 | _____________ |
| HOW | |||
| 6. | Describe the modes of delivery (e.g., face-to-face or by some other mechanism, such as internet or telephone) of the intervention and whether it was provided individually or in a group. | 5–6 | _____________ |
| WHERE | |||
| 7. | Describe the type(s) of location(s) where the intervention occurred, including any necessary infrastructure or relevant features. | 5–6 | _____________ |
| WHEN and HOW MUCH | |||
| 8. | Describe the number of times the intervention was delivered and over what period of time including the number of sessions, their schedule, and their duration, intensity or dose. | 5–6 | _____________ |
| TAILORING | |||
| 9. | If the intervention was planned to be personalised, titrated or adapted, then describe what, why, when, and how. | 4 | _____________ |
| MODIFICATIONS | |||
| 10. ǂ | If the intervention was modified during the course of the study, describe the changes (what, why, when, and how). | Not applicable | Recruitment location modified as per 2.2 |
| HOW WELL | |||
| 11. | Planned: If intervention adherence or fidelity was assessed, describe how and by whom, and if any strategies were used to maintain or improve fidelity, describe them. | 5—not assessed | _____________ |
| 12. ǂ | Actual: If intervention adherence or fidelity was assessed, describe the extent to which the intervention was delivered as planned. | Not assessed | _____________ |
** Authors—use N/A if an item is not applicable for the intervention being described. Reviewers—use ‘?’ if information about the element is not reported/not sufficiently reported. † If the information is not provided in the primary paper, give details of where this information is available. This may include locations such as a published protocol or other published papers (provide citation details) or a website (provide the URL). ǂ If completing the TIDieR checklist for a protocol, these items are not relevant to the protocol and cannot be described until the study is complete. * We strongly recommend using this checklist in conjunction with the TIDieR guide (see BMJ 2014; 348:g1687) which contains an explanation and elaboration for each item. * The focus of TIDieR is on reporting details of the intervention elements (and where relevant, comparison elements) of a study. Other elements and methodological features of studies are covered by other reporting statements and checklists and have not been duplicated as part of the TIDieR checklist. When a randomised trial is being reported, the TIDieR checklist should be used in conjunction with the CONSORT statement (see www.consort-statement.org) as an extension of Item 5 of the CONSORT 2010 Statement. When a clinical trial protocol is being reported, the TIDieR checklist should be used in conjunction with the SPIRIT statement as an extension of Item 11 of the SPIRIT 2013 Statement (see www.spirit-statement.org). For alternate study designs, TIDieR can be used in conjunction with the appropriate checklist for that study design (see www.equator-network.org).
Sample description by country for study 1.
| Ireland, All Groups | Group 1 | Group 2 | Group 3 | UK, All Groups | Group 1 | Group 2 | Group 3 | Malaysia, All Groups | Group 1 | Group 2 | Group 3 | India, All Groups | Group 1 | Group 2 | Group 3 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (mean, SD) | 37.1 (17.7) | 36.9 (17.4) | 36.7 (17.4) | 37.6 (18.5) | 46.1 (18.8) | 45.3 (19.0) | 46.8 (19.3) | 46.1 (18.3) | 19.7 (4.17) | 19.5 (4.19) | 20.0 (4.25) | 19.6 (4.14) | 22.6 (6.67) | 24.2 (8.72) | 22.8 (5.50) | 21.4 (5.18) |
| Women | 45.8% | 44.4% | 44.2% | 49.3% | 46.1% | 39.1% | 45.7% | 54.7% | 65.7% | 56.3% | 69.4% | 71.4% | 76.2% | 81.8% | 84.1% | 67.1% |
| Private health insurance † | 67.1% | 63.4% | 59.7% | 83% | † | † | † | † | 39.3% | 38.3% | 42.6% | 37.0% | 24.1% | 30.9% | 13.3% | 25.7% |
| Do you know someone who (% yes) | ||||||||||||||||
| has received an organ | 21.0% | 20% | 20% | 31% | 13.0% | 11.5% | 12.4% | 15.1% | 15.8% | 8.33% | 20.4% | 18.4% | 20.7% | 26% | 26.8% | 13.7% |
| needs an organ | 16.1% | 15.2% | 14.6% | 18.8% | 5.1% | 2.3% | 9.88% | 3.49% | 16.4% | 14.6% | 18.4% | 16.3% | 7.69% | 3.7% | 11.9% | 8.22% |
| has donated an organ | 12.8% | 12.6% | 15.2% | 10.5% | 8.27% | 4.6% | 9.88% | 10.5% | 11.0% | 8.33% | 14.3% | 10.2% | 23.0% | 26.0% | 26.2% | 19.2% |
| Ever donated blood | 37.2% | 34.4% | 38.2% | 39.1% | 46.9% | 46.0% | 48.2% | 46.5% | 24.7% | 27.1% | 34.7% | 12.2% | 18.2% | 14.6% | 16.7% | 21.9% |